מקטובי 15מ"ג - Mektovi 15 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EE Mitogen-activated protein kinase (MEK) inhibitors | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic MelanomaBinimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.BRAF V600E Mutation-Positive metastatic non-small cell lung cancer (NSCLC)Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma with a BRAF V600E mutation, as detected by an approved test. | ||||||||||||||||||
| |||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ק×××× 15×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ARRAY BIOPHARMA INC, USA |
| ×©× ××¢× ×ר×ש×× | MEDISON PHARMA LTD |
| ר×ש××× | ת×ר×× ××ש×: 7/2018. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 20/06/2025 |
השינוי האחרון נעשה בֹ־20 ביוני 2025 ב־19:07